Table 2. Immune Adverse Events in Both Cohorts.
| Adverse Event (n = 120) | Age Group, No. (%) | χ2 Test (P Value) | |
|---|---|---|---|
| ≤65 y (n = 67) |
>65 y (n = 53) |
||
| Immune-related adverse events | .24 | ||
| No | 31 (46) | 18 (34) | |
| Yes | 36 (54) | 38 (66) | |
| Adverse event | |||
| ≥1 (no other) | 33 (49) | 31 (58) | .41 |
| ≥1 (with other) | 37 (56) | 34 (64) | .42 |
| Time to first adverse event | |||
| Missing | 31 | 17 | |
| Mean | 7.8 | 6.19 | |
| Median (q1, q3) [range] | 7.0 (4.8, 10.0) [3-19] | 5.5 (4.0, 8.0) [3-14] | |
| Diarrhea enterocolitisa | .19 | ||
| No | 55 (83) | 38 (72) | |
| Yes | 11 (17) | 15 (28) | |
| Cutaneous eruption | >.99 | ||
| No | 54 (80) | 42 (79) | |
| Yes | 13 (20) | 11 (21) | |
| Thyroid | .81 | ||
| No | 59 (88) | 45 (75) | |
| Yes | 8 (12) | 8 (15) | |
| Hypophysis | .93 | ||
| No | 66 (99) | 51 (96) | |
| Yes | 1 (1) | 2 (4) | |
| Hepatitis | .84 | ||
| No | 54 (80) | 41 (77) | |
| Yes | 13 (20) | 12 (23) | |
| Vitiligo | >.99 | ||
| No | 60 (89) | 47 (89) | |
| Yes | 7 (11) | 6 (11) | |
| Other toxic effects | .04 | ||
| No | 58 (86) | 37 (70) | |
| Yes | 9 (14) | 16 (30) | |
Abbreviation: q, quartile.
a
n = 119.